Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

To approximate the physiologic state, GLP-1 or saline was administered intravenously and randomly at the beginning of a test meal served on a universal eating monitor to 6 obese subjects to test their hypothesis that GLP-1 influences termination of food intake (and thus food intake during a meal) and feelings of satiety in humans.

Why It Was Studied

The gut peptide glucagon-like peptide 1(7-36) amide (GLP-1) is released into the circulation after food intake.

Obese humans have been found to have an attenuated plasma GLP-1 response to a mixed meal.

Who Took Part

According to the abstract, 6 subjects were involved.

By PubMed's age tags, the people studied were adults, men only.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

PubMed files the paper under topics including Blood Glucose, C-Peptide, Gastric Emptying, Glucagon, Glucagon-Like Peptide 1, Hunger and Insulin.

What This Means in Plain Language

The paper is a randomized and double-blind study of Glucagon in 6 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1998 (The American journal of clinical nutrition), a journal based in United States.

More context: the Glucagon compound page, all human trials.